DE1617745A1 - Verfahren zur Herstellung eines Arzneimittels zur Verhinderung und Behandlung von Blutung,Schmerz,Schock und schaedlichen Traumawirkungen - Google Patents
Verfahren zur Herstellung eines Arzneimittels zur Verhinderung und Behandlung von Blutung,Schmerz,Schock und schaedlichen TraumawirkungenInfo
- Publication number
- DE1617745A1 DE1617745A1 DE19661617745 DE1617745A DE1617745A1 DE 1617745 A1 DE1617745 A1 DE 1617745A1 DE 19661617745 DE19661617745 DE 19661617745 DE 1617745 A DE1617745 A DE 1617745A DE 1617745 A1 DE1617745 A1 DE 1617745A1
- Authority
- DE
- Germany
- Prior art keywords
- substance
- bleeding
- group
- shock
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000032843 Hemorrhage Diseases 0.000 title claims description 24
- 208000034158 bleeding Diseases 0.000 title claims description 24
- 230000000740 bleeding effect Effects 0.000 title claims description 24
- 238000000034 method Methods 0.000 title claims description 22
- 230000000694 effects Effects 0.000 title claims description 16
- 230000035939 shock Effects 0.000 title claims description 15
- 208000014674 injury Diseases 0.000 title claims description 12
- 230000008733 trauma Effects 0.000 title claims description 12
- 230000009931 harmful effect Effects 0.000 title claims description 11
- 208000002193 Pain Diseases 0.000 title claims description 10
- 230000036407 pain Effects 0.000 title claims description 10
- 230000002265 prevention Effects 0.000 title claims description 9
- 239000003814 drug Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 21
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 16
- 239000001273 butane Substances 0.000 claims description 7
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- ICJBPZBRDLONIF-UHFFFAOYSA-N hexane-1,1,1,2,2,3-hexol Chemical class CCCC(O)C(O)(O)C(O)(O)O ICJBPZBRDLONIF-UHFFFAOYSA-N 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 125000003071 maltose group Chemical group 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 27
- -1 cyclic hexane hexols Chemical class 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000012260 Accidental injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42507565A | 1965-01-12 | 1965-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1617745A1 true DE1617745A1 (de) | 1971-04-08 |
Family
ID=23685031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19661617745 Pending DE1617745A1 (de) | 1965-01-12 | 1966-01-12 | Verfahren zur Herstellung eines Arzneimittels zur Verhinderung und Behandlung von Blutung,Schmerz,Schock und schaedlichen Traumawirkungen |
Country Status (9)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2839311A1 (de) * | 1978-02-24 | 1979-09-06 | Mitsui Toatsu Chemicals | Pharmazeutisches praeparat gegen geschwuere |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3911915A (en) * | 1972-09-05 | 1975-10-14 | Einstein Coll Med | Dialytic introduction of maltose into bloodstream |
| US4474806A (en) * | 1982-05-10 | 1984-10-02 | Merck & Co., Inc. | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062898A (en) * | 1963-06-14 | 1967-03-22 | Evans Medical Ltd | Pharmaceutical compositions containing protamines |
-
1965
- 1965-01-12 US US425075A patent/US3470295A/en not_active Expired - Lifetime
-
1966
- 1966-01-11 IL IL24953A patent/IL24953A/en unknown
- 1966-01-11 GB GB1163/66A patent/GB1139242A/en not_active Expired
- 1966-01-12 ES ES0321672A patent/ES321672A1/es not_active Expired
- 1966-01-12 AT AT27666A patent/AT297920B/de not_active IP Right Cessation
- 1966-01-12 DE DE19661617745 patent/DE1617745A1/de active Pending
- 1966-01-12 NL NL6600406A patent/NL6600406A/xx unknown
- 1966-01-12 BE BE675018D patent/BE675018A/xx unknown
- 1966-01-14 BR BR176372/66A patent/BR6676372D0/pt unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2839311A1 (de) * | 1978-02-24 | 1979-09-06 | Mitsui Toatsu Chemicals | Pharmazeutisches praeparat gegen geschwuere |
Also Published As
| Publication number | Publication date |
|---|---|
| BR6676372D0 (pt) | 1973-09-06 |
| AT297920B (de) | 1972-04-10 |
| BE675018A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-05-03 |
| NL6600406A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-07-13 |
| US3470295A (en) | 1969-09-30 |
| GB1139242A (en) | 1969-01-08 |
| ES321672A1 (es) | 1967-01-16 |
| IL24953A (en) | 1970-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69535607T2 (de) | Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten | |
| DE2046119C2 (de) | Mittel zur Behandlung von Akne | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| DE4200080A1 (de) | Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung | |
| DE3413052A1 (de) | Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen | |
| DE2802924A1 (de) | Heilmittel zur behandlung von akne | |
| EP0254869A2 (de) | Verwendung von Aryloxycarbonsäure-Derivaten gegen dermatologische Erkrankungen | |
| DE69614375T2 (de) | Dermatologische zubereitung zur behandlung von aktinischen keratosen | |
| DE1902227A1 (de) | Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung | |
| DE3022281C2 (de) | Von Alkaloiden befreiter wäßriger Extrakt aus Aconitwurzeln und diesen Extrakt als Wirkstoff enthaltende pharmazeutische Zusammensetzung | |
| DE2740349A1 (de) | Heilmittel zur linderung der symptome trockener haut | |
| DE2802273C3 (de) | Verfahren zur Herstellung von Suppositorien aus Aminoglycid-Antibiotica | |
| EP0037488A2 (de) | Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen | |
| DE1804801C3 (de) | Mittel zur Aknebehandlung | |
| WO1989000853A1 (en) | Agent containing salicylic acid for treating lepidosis | |
| EP0668768B1 (de) | Zusammensetzung zur bekämpfung von dermatomykosen und deren erregern sowie von schweissbildung und körpergeruch | |
| DE1617745A1 (de) | Verfahren zur Herstellung eines Arzneimittels zur Verhinderung und Behandlung von Blutung,Schmerz,Schock und schaedlichen Traumawirkungen | |
| EP0432638A1 (de) | Kombinationspräparate enthaltend Chloramphenicol, Gentamicin und Nystatin als aktive Wirkstoffe zur topischen Behandlung entzündlicher Hauterkrankungen | |
| DE4300969C2 (de) | Verwendung von Malotilat zum Beschleunigen der Wundheilung bei Hautverbrennungen | |
| DE2741599A1 (de) | Mittel zur behandlung von akne vulgaris | |
| DE2720420A1 (de) | Wirkstoffkombination gegen sonnenerythem und diese enthaltendes arzneimittel | |
| DE3504355A1 (de) | Mittel zur regenerierung der haut | |
| DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
| DE3707532C2 (de) | Verwendung einer Kombination von Extr. Gingko biloba oder mindestens einem Gingkolid und Acetylsalicylsäure oder DL-Lysin-mono-acetylsalicylat oder Diflunisal zur Behandlung von Verbrennungen, Verbrühungen, Strahlenschäden und Erfrierungen | |
| DE2803592A1 (de) | Therapeutisches mittel |